Clinical Trial Update: Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tegaserod for gastroesophageal reflux disease in patients with incomplete response to proton pump inhibitors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Zelnorm (tegaserod)

Snippet

Sponsor: Novartis | Conditions: Gastroesophageal Reflux Disease (GERD) | Phase 3 | Status: COMPLETED